Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Curto-Barredo, Laiaca
- dc.contributor.author Yélamos López, Joséca
- dc.contributor.author Gimeno Martínez, Ramónca
- dc.contributor.author Mojal, Sergioca
- dc.contributor.author Pujol Vallverdú, Ramon Mariaca
- dc.contributor.author Giménez Arnau, Anna Mariaca
- dc.date.accessioned 2018-01-17T08:00:25Z
- dc.date.available 2018-01-17T08:00:25Z
- dc.date.issued 2016
- dc.description.abstract The basophil activation test showing CD63 up regulation could be a specific and sensitive in vitro complementary text to the in vivo autologous serum skin test for the activity assessment of the patients suffering autoimmune chronic spontaneous urticaria. The aim of this study is to define the basophil activation test as a useful tool in clinical practice in order to identify those patients with more active disease. METHODS: We screened 139 patients (96 women) diagnosed of chronic spontaneous urticaria using simultaneously autologous serum skin test and basophil activation test and their relationship with disease activity. RESULTS: Positive autologous serum skin test was found in 56.8%; from them, 31.6% were basophil activation test positive. Negative autologous serum skin test result was found in the 43.2% of the sample that showed negative CD63 expression results in all cases, except one. Patients with positive autologous serum skin test and positive CD63 by basophil activation test showed significant higher Urticaria Activity Score of 7 days (P = 0.004) and of 3 weeks (P = 0.001) than patients with positive autologous serum skin test and negative CD63 (mean ± standard deviation [SD] 26.57 ± 10.56 versus 18.40 ± 12.05 for the Urticaria Activity Score of 7 days and 56.47 ± 23.78 versus 39.88 ± 25.44 for the Urticaria Activity Score of 3 weeks). CONCLUSIONS: The CD63 expression on basophils appears as a reliable in vitro marker, useful in clinical practice in combination with autologous serum skin test to define chronic spontaneous urticaria patients with the highest urticaria activity that impairs a normal life.
- dc.format.mimetype application/pdfca
- dc.identifier.citation Curto-Barredo L, Yelamos J, Gimeno R, Mojal S, Pujol RM, Giménez-Arnau A. Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease. Immun Inflamm Dis. 2016 Oct 4;4(4):441-445. DOI: 10.1002/iid3.125
- dc.identifier.doi http://dx.doi.org/10.1002/iid3.125
- dc.identifier.issn 2050-4527
- dc.identifier.uri http://hdl.handle.net/10230/33651
- dc.language.iso eng
- dc.publisher Wileyca
- dc.relation.ispartof Immunity, inflammation and disease. 2016 Oct 4;4(4):441-5
- dc.rights Copyright © 2016 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. This is an open access article under the terms of the https://creativecommons.org/licenses/by/4.0/, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.keyword Autologous serum skin test
- dc.subject.keyword Basophil activation test
- dc.subject.keyword Chronic spontaneous urticaria
- dc.subject.other Urticaria
- dc.title Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active diseaseca
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion